Core Viewpoint - The company has achieved significant growth in its financial performance, with a focus on enhancing operational efficiency and expanding its market presence in the pharmaceutical industry. Group 1: Financial Performance - The net profit attributable to the parent company reached 528 million yuan, representing a year-on-year increase of 19.14%, while the net profit excluding non-recurring gains and losses was 511 million yuan, up 44.98% year-on-year [2]. - The main business revenue from the pharmaceutical industry was 2.161 billion yuan, reflecting a year-on-year growth of 17.82% [3]. - The medical service segment reported a revenue of 449 million yuan, marking a year-on-year increase of 30.15% [9]. Group 2: Business Strategy and Operations - The company is consolidating its core advantages in the anorectal field and has launched a new series of sanitary wet wipes targeting anal care, enhancing its competitive edge [4]. - The company has strengthened its brand marketing through various channels, including content marketing and strategic partnerships, to expand its market reach [5]. - The company is focusing on optimizing its research and development structure, particularly in strategic areas such as anorectal, ophthalmology, and dermatology, with multiple projects making progress [6]. Group 3: Governance and Compliance - The board of directors has held six meetings during the reporting period, reviewing 23 proposals, including regular reports and profit distribution [10]. - The independent directors have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations while maintaining the interests of all shareholders [23][24]. - The supervisory board has conducted effective oversight of the company's operations, financial status, and compliance with internal controls [20][21]. Group 4: Future Outlook - The pharmaceutical industry is expected to face stricter regulations and price governance, necessitating adjustments in market and pricing strategies [14]. - The retail pharmacy sector is undergoing transformation, with opportunities arising from the government's focus on enhancing health promotion functions [15]. - The company aims to continue its focus on the health and wellness market, leveraging advancements in artificial intelligence to enhance operational efficiency and service innovation [16][18].

| 6 月金股组合 | | | --- | --- | | 股票代码 | 股票名称 | | 002352.SZ | 顺丰控股 | | 688019.SH | 安集科技 | | 688198.SH | 佰仁医疗 | | 000524.SZ | 岭南控股 | | 600600.SH | 青岛啤酒 | | 688507.SH | 索辰科技 | 中银晨会聚焦-20250606 ■重点关注 【宏观经济】5 月 PMI 数据点评*陈琦 朱启兵。5 月内、外需表现分化。外 贸环境短期改善，对 5 月制造企业生产意愿有所提振。高技术制造业及高技 术服务业景气度均处于扩张区间。 【社会服务】2025 年端午旅游数据点评*李小民 宋环翔。端午假期国内文 旅市场回归短途休闲游为主导，亲子经济占比高、文体旅融合带动文旅消费， 跨境游市场持续火热并有望延续优秀表现。 【医药生物】马应龙*刘恩阳。公司发布 24 年年报及 25 年一季报，24 年公 司实现营业收入 37.28 亿元，同比增长 18.85%；利润总额为 6.58 亿元，同比 增长 25.32%；实现归母净利润 5.28 亿元，同比增长 19.14%。25 年一季报， 公司 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 29.00 and a sector rating of "Outperform" [1][3]. Core Views - The company has demonstrated steady growth in its performance, with a 2024 revenue of RMB 3.728 billion, representing an 18.85% year-on-year increase, and a net profit of RMB 528 million, up 19.14% year-on-year. The first quarter of 2025 shows a revenue of RMB 969 million, a 1.48% increase, and a net profit of RMB 204 million, up 2.99% year-on-year. The company has a strong brand presence in the anorectal field and is expected to gain new growth from its health business [3][5]. - The company is expected to see continued growth in its health business, particularly with the launch of new products targeting the anorectal health management market, which is anticipated to enhance brand recognition and sales [8]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of RMB 3.728 billion, with a growth rate of 18.9%. The projected revenues for 2025, 2026, and 2027 are RMB 4.204 billion, RMB 4.720 billion, and RMB 5.250 billion, respectively, with growth rates of 12.8%, 12.3%, and 11.2% [7]. - The net profit for 2024 was RMB 528 million, with a growth rate of 19.1%. The projected net profits for the following years are RMB 616 million, RMB 714 million, and RMB 798 million, with growth rates of 16.6%, 16.0%, and 11.7% [7]. Valuation - The report slightly adjusts the profit forecast, estimating the net profit for 2025-2027 to be RMB 616 million, RMB 714 million, and RMB 798 million, respectively. The corresponding earnings per share (EPS) are projected to be RMB 1.43, RMB 1.66, and RMB 1.85. The price-to-earnings (P/E) ratios for these years are expected to be 20.3, 17.5, and 15.7 times [5][7]. Market Position - The company has a strong foothold in the anorectal market, with significant brand advantages. The health sector is anticipated to provide new growth opportunities, particularly through the introduction of innovative products and enhanced market coverage [3][8].